An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs IFX 1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Pharmacodynamics
- Sponsors InflaRx
- 20 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 20 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.